{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:28:03Z","timestamp":1791836883710,"version":"4.3.4"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-025-11295-4","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T12:59:15Z","timestamp":1764593955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunological mechanisms underlying the novel application of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) in graft-versus-host disease (GvHD) therapy"],"prefix":"10.1007","volume":"53","author":[{"given":"Fatemeh","family":"Ahangari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Alimohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mahmoud","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"3","key":"11295_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0046-8177(71)80006-0","volume":"2","author":"JH Kersey","year":"1971","unstructured":"Kersey JH, Meuwissen HJ, Good RA (1971) Graft versus host reactions following transplantation of allogeneic hematopoietic cells. Hum Pathol 2(3):389\u2013402","journal-title":"Hum Pathol"},{"key":"11295_CR2","doi-asserted-by":"crossref","unstructured":"MacDonald KP, Shlomchik WD, Reddy P (2013) Biology of graft-versus-host responses: recent insights. Biology of blood and marrow transplantation: journal of the American society for blood and marrow transplantation. 19(1 Suppl):S10\u2013S14","DOI":"10.1016\/j.bbmt.2012.11.005"},{"issue":"8","key":"11295_CR3","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","volume":"18","author":"PJ Martin","year":"2012","unstructured":"Martin PJ et al (2012) First- and Second-Line systemic treatment of acute Graft-versus-Host disease: recommendations of the American society of blood and marrow transplantation. Biol Blood Marrow Transplant 18(8):1150\u20131163","journal-title":"Biol Blood Marrow Transplant"},{"key":"11295_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-1-4939-3584-0_7","volume":"1416","author":"M Gnecchi","year":"2016","unstructured":"Gnecchi M et al (2016) Paracrine mechanisms of mesenchymal stem cells in tissue repair. Methods Mol Biol 1416:123\u2013146","journal-title":"Methods Mol Biol"},{"issue":"10","key":"11295_CR5","doi-asserted-by":"publisher","first-page":"7043","DOI":"10.1002\/jcp.29601","volume":"235","author":"M Shahir","year":"2020","unstructured":"Shahir M et al (2020) Effect of mesenchymal stem cell-derived exosomes on the induction of mouse tolerogenic dendritic cells. J Cell Physiol 235(10):7043\u20137055","journal-title":"J Cell Physiol"},{"issue":"3","key":"11295_CR6","first-page":"1230","volume":"11","author":"S Yin","year":"2019","unstructured":"Yin S et al (2019) Human umbilical cord mesenchymal stem cells and exosomes: bioactive ways of tissue injury repair. Am J Translational Res 11(3):1230\u20131240","journal-title":"Am J Translational Res"},{"issue":"10","key":"11295_CR7","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s42255-021-00467-8","volume":"3","author":"E Milbank","year":"2021","unstructured":"Milbank E et al (2021) Small extracellular vesicle-mediated targeting of hypothalamic AMPK\u03b11 corrects obesity through BAT activation. Nat Metabolism 3(10):1415\u20131431","journal-title":"Nat Metabolism"},{"key":"11295_CR8","doi-asserted-by":"publisher","unstructured":"Tahmasebi S, Alimohammadi M, Khorasani S, et al (2025) Pro-tumorigenic and anti-tumorigenic roles of pro-inflammatory cytokines in cancer. In: Rezaei N (ed) Cancer Immunology: The Immune System and Tumor. Handb Cancer Immunol. Springer, Cham 1:pp 529\u2013553. https:\/\/doi.org\/10.1007\/978-3-032-00749-0_25","DOI":"10.1007\/978-3-032-00749-0_25"},{"issue":"5","key":"11295_CR9","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/0952-7915(93)90139-J","volume":"5","author":"JLM Ferrara","year":"1993","unstructured":"Ferrara JLM (1993) Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol 5(5):794\u2013799","journal-title":"Curr Opin Immunol"},{"issue":"9","key":"11295_CR10","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1182\/blood.V95.9.2754.009k25_2754_2759","volume":"95","author":"GR Hill","year":"2000","unstructured":"Hill GR, Ferrara JLM (2000) The primacy of the Gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95(9):2754\u20132759","journal-title":"Blood"},{"issue":"1","key":"11295_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","volume":"9","author":"F Malard","year":"2023","unstructured":"Malard F et al (2023) Acute graft-versus-host disease. Nat Reviews Disease Primers 9(1):27","journal-title":"Nat Reviews Disease Primers"},{"issue":"18","key":"11295_CR12","first-page":"1657","volume":"138","author":"R Chakraverty","year":"2021","unstructured":"Chakraverty R, Teshima T (2021) Graft-versus-host disease: a disorder of tissue regeneration and repair. Blood. J Am Soc Hematol 138(18):1657\u20131665","journal-title":"J Am Soc Hematol"},{"issue":"8","key":"11295_CR13","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1002\/hep4.1965","volume":"6","author":"AH Yang","year":"2022","unstructured":"Yang AH et al (2022) Abnormal liver tests are not sufficient for diagnosis of hepatic graft-versus\u2010host disease in critically ill patients. Hepatol Commun 6(8):2210\u20132220","journal-title":"Hepatol Commun"},{"key":"11295_CR14","doi-asserted-by":"publisher","first-page":"1039938","DOI":"10.3389\/fped.2022.1039938","volume":"10","author":"L Hiskey","year":"2022","unstructured":"Hiskey L et al (2022) Prevention and management of human cytomegalovirus in pediatric HSCT recipients: A review. Front Pead 10:1039938","journal-title":"Front Pead"},{"key":"11295_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fimmu.2017.00079","volume":"8","author":"S Ghimire","year":"2017","unstructured":"Ghimire S et al (2017) Pathophysiology of GvHD and other HSCT-Related major complications. Front Immunol 8:79\u201379","journal-title":"Front Immunol"},{"issue":"1","key":"11295_CR16","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.bbmt.2011.10.021","volume":"18","author":"CL Kitko","year":"2012","unstructured":"Kitko CL, White ES, Baird K (2012) Fibrotic and sclerotic manifestations of chronic Graft-versus-Host disease. Biol Blood Marrow Transplant 18(1):S46\u2013S52","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"11295_CR17","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1513\/AnnalsATS.202008-999RL","volume":"18","author":"DN O\u2019Dwyer","year":"2020","unstructured":"O\u2019Dwyer DN et al (2020) Concurrent reductions in spirometry predict mortality and bronchiolitis obliterans in chronic Graft-versus-Host disease. Annals Am Thorac Soc 18(4):720\u2013723","journal-title":"Annals Am Thorac Soc"},{"issue":"6","key":"11295_CR18","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.bbmt.2010.08.023","volume":"17","author":"Y Wang","year":"2011","unstructured":"Wang Y et al (2011) Superior Graft-versus-Leukemia effect associated with transplantation of haploidentical compared with HLA-Identical sibling donor grafts for High-Risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant 17(6):821\u2013830","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"11295_CR19","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1038\/s41375-025-02724-1","volume":"39","author":"J Schetelig","year":"2025","unstructured":"Schetelig J et al (2025) Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings. Leukemia 39(10):2523\u20132532","journal-title":"Leukemia"},{"issue":"2","key":"11295_CR20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41409-019-0597-y","volume":"54","author":"A Pierini","year":"2019","unstructured":"Pierini A et al (2019) T cell depletion and no post transplant immune suppression allow separation of graft versus leukemia from graft versus host disease. Bone Marrow Transplant 54(2):775\u2013779","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"11295_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1172\/JCI17601","volume":"112","author":"BE Anderson","year":"2003","unstructured":"Anderson BE et al (2003) Memory CD4\u2009+\u2009T cells do not induce graft-versus-host disease. J Clin Investig 112(1):101\u2013108","journal-title":"J Clin Investig"},{"issue":"2","key":"11295_CR22","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/bmt.2013.107","volume":"49","author":"T Ruutu","year":"2014","unstructured":"Ruutu T et al (2014) Prophylaxis and treatment of GVHD: EBMT\u2013ELN working group recommendations for a standardized practice. Bone Marrow Transplant 49(2):168\u2013173","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"11295_CR23","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00007890-199310000-00005","volume":"56","author":"R Storb","year":"1993","unstructured":"Storb R et al (1993) FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. Transplantation 56(4):800\u2013807","journal-title":"Transplantation"},{"issue":"12","key":"11295_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJM198603203141201","volume":"314","author":"R Storb","year":"1986","unstructured":"Storb R et al (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314(12):729\u2013735","journal-title":"N Engl J Med"},{"issue":"8","key":"11295_CR25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.bbmt.2009.04.004","volume":"15","author":"W Sabry","year":"2009","unstructured":"Sabry W et al (2009) Graft-versus-Host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-Matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biol Blood Marrow Transplant 15(8):919\u2013929","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"11295_CR26","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","volume":"124","author":"CG Kanakry","year":"2014","unstructured":"Kanakry CG et al (2014) Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood 124(25):3817\u20133827","journal-title":"Blood"},{"issue":"1","key":"11295_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1182\/asheducation-2018.1.228","volume":"2018","author":"BK Hamilton","year":"2018","unstructured":"Hamilton BK (2018) Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation. Hematol Am Soc Hematol Educ Program 2018(1):228\u2013235","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"8","key":"11295_CR28","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","volume":"124","author":"C Cutler","year":"2014","unstructured":"Cutler C et al (2014) Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 124(8):1372\u20131377","journal-title":"Blood"},{"issue":"1","key":"11295_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(13)70512-6","volume":"15","author":"SW Choi","year":"2014","unstructured":"Choi SW et al (2014) Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic Haemopoietic stem-cell transplantation: a phase 1\/2 trial. Lancet Oncol 15(1):87\u201395","journal-title":"Lancet Oncol"},{"issue":"13","key":"11295_CR30","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1182\/blood-2007-08-106005","volume":"110","author":"R Zeiser","year":"2007","unstructured":"Zeiser R et al (2007) Preemptive HMG-CoA reductase Inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood 110(13):4588\u20134598","journal-title":"Blood"},{"issue":"Supplement 1","key":"11295_CR31","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1182\/blood-2023-188971","volume":"142","author":"J Fuqua","year":"2023","unstructured":"Fuqua J et al (2023) Statin use and its effects on survival outcomes and rates of Gvhd in allogeneic stem cell transplant patients: results from Real-World cohorts. Blood 142(Supplement 1):7004\u20137004","journal-title":"Blood"},{"issue":"11","key":"11295_CR32","first-page":"701e1","volume":"29","author":"N Rashid","year":"2023","unstructured":"Rashid N et al (2023) Impact of donor Statin treatment on Graft-versus-Host disease after allogeneic hematopoietic cell transplantation. Transplantation Cell Therapy Official Publication Am Soc Transplantation Cell Therapy 29(11):701e1\u2013701e8","journal-title":"Transplantation Cell Therapy Official Publication Am Soc Transplantation Cell Therapy"},{"issue":"1","key":"11295_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2016-08-686659","volume":"129","author":"CS Cutler","year":"2017","unstructured":"Cutler CS, Koreth J, Ritz J (2017) Mechanistic approaches for the prevention and treatment of chronic GVHD. Blood 129(1):22\u201329","journal-title":"Blood"},{"issue":"13","key":"11295_CR34","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S1470-2045(14)71017-4","volume":"15","author":"GA Kennedy","year":"2014","unstructured":"Kennedy GA et al (2014) Addition of interleukin-6 Inhibition with Tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1\/2 trial. Lancet Oncol 15(13):1451\u20131459","journal-title":"Lancet Oncol"},{"issue":"1","key":"11295_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/2040620717741860","volume":"9","author":"L Hill","year":"2017","unstructured":"Hill L et al (2017) New and emerging therapies for acute and chronic graft versus host disease. Therapeutic Adv Hematol 9(1):21\u201346","journal-title":"Therapeutic Adv Hematol"},{"issue":"3","key":"11295_CR36","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41375-019-0625-3","volume":"34","author":"C Riegel","year":"2020","unstructured":"Riegel C et al (2020) Efficient treatment of murine acute GvHD by in vitro expanded donor regulatory T cells. Leukemia 34(3):895\u2013908","journal-title":"Leukemia"},{"issue":"14","key":"11295_CR37","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","volume":"119","author":"OC Goodyear","year":"2012","unstructured":"Goodyear OC et al (2012) Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 119(14):3361\u20133369","journal-title":"Blood"},{"key":"11295_CR38","doi-asserted-by":"crossref","unstructured":"Ken-ichi M et al (2013) Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease. Science Translational Medicine, 5(179): p. 179ra43-179ra43","DOI":"10.1126\/scitranslmed.3005265"},{"issue":"14","key":"11295_CR39","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","volume":"117","author":"M Di Ianni","year":"2011","unstructured":"Di Ianni M et al (2011) Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117(14):3921\u20133928","journal-title":"Blood"},{"issue":"8","key":"11295_CR40","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nri2132","volume":"7","author":"AE Morelli","year":"2007","unstructured":"Morelli AE, Thomson AW (2007) Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 7(8):610\u2013621","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"11295_CR41","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/sji.12113","volume":"78","author":"J Yang","year":"2013","unstructured":"Yang J et al (2013) Third-party tolerogenic dendritic cells reduce Allo-reactivity in vitro and ameliorate the severity of acute graft-Versus-host disease in Allo-bone marrow transplantation. Scand J Immunol 78(6):486\u2013496","journal-title":"Scand J Immunol"},{"issue":"2","key":"11295_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1189\/jlb.5MR1116-464R","volume":"102","author":"BH Koehn","year":"2017","unstructured":"Koehn BH, Blazar BR (2017) Role of myeloid-derived suppressor cells in allogeneic hematopoietic cell transplantation. J Leukoc Biol 102(2):335\u2013341","journal-title":"J Leukoc Biol"},{"issue":"9","key":"11295_CR43","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1182\/blood-2015-01-624163","volume":"126","author":"JJ Messmann","year":"2015","unstructured":"Messmann JJ et al (2015) In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity. Blood 126(9):1138\u20131148","journal-title":"Blood"},{"issue":"25","key":"11295_CR44","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.1182\/blood-2010-06-287839","volume":"116","author":"SL Highfill","year":"2010","unstructured":"Highfill SL et al (2010) Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1\u2013dependent mechanism that is up-regulated by interleukin-13. Blood 116(25):5738\u20135747","journal-title":"Blood"},{"key":"11295_CR45","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.clim.2017.11.005","volume":"187","author":"Y Lin","year":"2018","unstructured":"Lin Y et al (2018) mTOR inhibitor Rapamycin induce polymorphonuclear myeloid-derived suppressor cells mobilization and function in protecting against acute graft-versus-host disease after bone marrow transplantation. Clin Immunol 187:122\u2013131","journal-title":"Clin Immunol"},{"issue":"13","key":"11295_CR46","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1182\/blood-2015-03-634691","volume":"126","author":"BH Koehn","year":"2015","unstructured":"Koehn BH et al (2015) GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. Blood 126(13):1621\u20131628","journal-title":"Blood"},{"issue":"12","key":"11295_CR47","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1016\/j.bbmt.2018.07.004","volume":"24","author":"J-Y Lim","year":"2018","unstructured":"Lim J-Y et al (2018) Ex vivo generated human cord blood Myeloid-Derived suppressor cells attenuate murine chronic Graft-versus-Host diseases. Biol Blood Marrow Transplant 24(12):2381\u20132396","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"11295_CR48","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1182\/blood-2015-12-688739","volume":"127","author":"F Malard","year":"2016","unstructured":"Malard F et al (2016) Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival. Blood 127(14):1828\u20131835","journal-title":"Blood"},{"issue":"22","key":"11295_CR49","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1182\/blood-2014-11-612762","volume":"125","author":"D Schneidawind","year":"2015","unstructured":"Schneidawind D et al (2015) Third-party CD4\u2009+\u2009invariant natural killer T cells protect from murine GVHD lethality. Blood 125(22):3491\u20133500","journal-title":"Blood"},{"issue":"21","key":"11295_CR50","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","volume":"115","author":"JA Olson","year":"2010","unstructured":"Olson JA et al (2010) NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 115(21):4293\u20134301","journal-title":"Blood"},{"issue":"6","key":"11295_CR51","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.leukres.2011.11.009","volume":"36","author":"M Tanaka","year":"2012","unstructured":"Tanaka M et al (2012) The impact of the dose of natural killer cells in the graft on severe acute graft-versus-host disease after unrelated bone marrow transplantation. Leuk Res 36(6):699\u2013703","journal-title":"Leuk Res"},{"issue":"5411","key":"11295_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1126\/science.284.5411.143","volume":"284","author":"MF Pittenger","year":"1999","unstructured":"Pittenger MF et al (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284(5411):143\u2013147","journal-title":"Science"},{"key":"11295_CR53","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.3389\/fimmu.2018.03041","volume":"9","author":"Y-J Chang","year":"2018","unstructured":"Chang Y-J, Zhao X-Y, Huang X-J (2018) Strategies for enhancing and preserving Anti-leukemia effects without aggravating Graft-Versus-Host disease. Front Immunol 9:3041\u20133041","journal-title":"Front Immunol"},{"issue":"1","key":"11295_CR54","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1038\/emm.2013.2","volume":"45","author":"E-J Kim","year":"2013","unstructured":"Kim E-J, Kim N, Cho S-G (2013) The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation. Exp Mol Med 45(1):e2\u2013e2","journal-title":"Exp Mol Med"},{"issue":"1","key":"11295_CR55","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1365-2249.2009.03874.x","volume":"156","author":"K English","year":"2009","unstructured":"English K et al (2009) Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4\u2009+\u2009CD25Highforkhead box P3\u2009+\u2009regulatory T cells. Clin Experimental Immunol 156(1):149\u2013160","journal-title":"Clin Experimental Immunol"},{"issue":"10","key":"11295_CR56","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1002\/eji.201141499","volume":"41","author":"MM Duffy","year":"2011","unstructured":"Duffy MM et al (2011) Mesenchymal stem cell Inhibition of T-helper 17 cell- differentiation is triggered by cell\u2013cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol 41(10):2840\u20132851","journal-title":"Eur J Immunol"},{"issue":"416","key":"11295_CR57","doi-asserted-by":"publisher","first-page":"eaam7828","DOI":"10.1126\/scitranslmed.aam7828","volume":"9","author":"G Antonio","year":"2017","unstructured":"Antonio G et al (2017) Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated Immunomodulation. Sci Transl Med 9(416):eaam7828\u2013eaam7828","journal-title":"Sci Transl Med"},{"issue":"4","key":"11295_CR58","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.4049\/jimmunol.1700901","volume":"201","author":"V van Hoeven","year":"2018","unstructured":"van Hoeven V et al (2018) Mesenchymal stromal cells stimulate the proliferation and IL-22 production of group 3 innate lymphoid cells. J Immunol 201(4):1165\u20131165","journal-title":"J Immunol"},{"issue":"8","key":"11295_CR59","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41581-018-0023-5","volume":"14","author":"Y Shi","year":"2018","unstructured":"Shi Y et al (2018) Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol 14(8):493\u2013507","journal-title":"Nat Rev Nephrol"},{"key":"11295_CR60","first-page":"421","volume":"15","author":"M Ullah","year":"2019","unstructured":"Ullah M, Liu DD, Thakor AS (2019) Mesenchymal Stromal Cell Homing: Mech Strategies Improv iScience 15:421\u2013438","journal-title":"Mesenchymal Stromal Cell Homing: Mech Strategies Improv iScience"},{"issue":"9419","key":"11295_CR61","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","volume":"363","author":"K Le Blanc","year":"2004","unstructured":"Le Blanc K et al (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419):1439\u20131441","journal-title":"Lancet"},{"issue":"1","key":"11295_CR62","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-022-01240-4","volume":"15","author":"K Zhao","year":"2022","unstructured":"Zhao K et al (2022) Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol 15(1):22","journal-title":"J Hematol Oncol"},{"issue":"11","key":"11295_CR63","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41591-020-1050-x","volume":"26","author":"AJC Bloor","year":"2020","unstructured":"Bloor AJC et al (2020) Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. Nat Med 26(11):1720\u20131725","journal-title":"Nat Med"},{"issue":"5","key":"11295_CR64","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.bbmt.2019.08.029","volume":"26","author":"P Kebriaei","year":"2020","unstructured":"Kebriaei P et al (2020) A phase 3 randomized study of Remestemcel-L versus placebo added to Second-Line therapy in patients with Steroid-Refractory acute Graft-versus-Host disease. Biol Blood Marrow Transplant 26(5):835\u2013844","journal-title":"Biol Blood Marrow Transplant"},{"key":"11295_CR65","doi-asserted-by":"publisher","unstructured":"Fisher SA et al (2019) Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. Cochrane Database Syst Rev 1(1):CD009768. https:\/\/doi.org\/10.1002\/14651858.CD009768.pub2","DOI":"10.1002\/14651858.CD009768.pub2"},{"issue":"10","key":"11295_CR66","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jcyt.2019.08.002","volume":"21","author":"S Viswanathan","year":"2019","unstructured":"Viswanathan S et al (2019) Mesenchymal stem versus stromal cells: international society for cell & gene therapy (ISCT\u00ae) mesenchymal stromal cell committee position statement on nomenclature. Cytotherapy 21(10):1019\u20131024","journal-title":"Cytotherapy"},{"issue":"10","key":"11295_CR67","doi-asserted-by":"publisher","first-page":"e47559","DOI":"10.1371\/journal.pone.0047559","volume":"7","author":"MM Lalu","year":"2012","unstructured":"Lalu MM et al (2012) Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE 7(10):e47559","journal-title":"PLoS ONE"},{"issue":"8","key":"11295_CR68","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3324\/haematol.2015.140368","volume":"101","author":"K Zyrafete","year":"2016","unstructured":"Zyrafete K et al (2016) Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. Haematologica 101(8):985\u2013994","journal-title":"Haematologica"},{"issue":"1","key":"11295_CR69","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s13287-025-04361-y","volume":"16","author":"M Mebarki","year":"2025","unstructured":"Mebarki M et al (2025) Pooling umbilical cord-mesenchymal stromal cells derived from selected multiple donors reduces donor-dependent variability and improves their Immunomodulatory properties. Stem Cell Res Ther 16(1):252","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"11295_CR70","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/sctm.17-0167","volume":"7","author":"O Ringden","year":"2018","unstructured":"Ringden O et al (2018) Placenta-Derived decidua stromal cells for treatment of severe acute Graft-Versus-Host disease. STEM CELLS Translational Med 7(4):325\u2013331","journal-title":"STEM CELLS Translational Med"},{"issue":"4","key":"11295_CR71","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/stmcls\/sxae003","volume":"42","author":"O Ringd\u00e9n","year":"2024","unstructured":"Ringd\u00e9n O, Sadeghi B (2024) Placenta-Derived decidua stromal cells: A new frontier in the therapy of acute Graft-Versus-Host disease. Stem Cells 42(4):291\u2013300","journal-title":"Stem Cells"},{"issue":"1","key":"11295_CR72","doi-asserted-by":"publisher","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","volume":"7","author":"C Th\u00e9ry","year":"2018","unstructured":"Th\u00e9ry C et al (2018) Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 7(1):1535750\u20131535750","journal-title":"J Extracell Vesicles"},{"issue":"4","key":"11295_CR73","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/leu.2014.41","volume":"28","author":"L Kordelas","year":"2014","unstructured":"Kordelas L et al (2014) MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 28(4):970\u2013973","journal-title":"Leukemia"},{"issue":"8","key":"11295_CR74","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1080\/08820139.2020.1801720","volume":"50","author":"M Taghavi-Farahabadi","year":"2021","unstructured":"Taghavi-Farahabadi M et al (2021) Wharton\u2019s jelly mesenchymal stem cells exosomes and conditioned media increased neutrophil lifespan and phagocytosis capacity. Immunol Investig 50(8):1042\u20131057","journal-title":"Immunol Investig"},{"issue":"2","key":"11295_CR75","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/jcmm.17114","volume":"26","author":"AH Norooznezhad","year":"2022","unstructured":"Norooznezhad AH et al (2022) Human placental mesenchymal stromal cell-derived exosome-enriched extracellular vesicles for chronic cutaneous graft-versus-host disease: A case report. J Cell Mol Med 26(2):588\u2013592","journal-title":"J Cell Mol Med"},{"key":"11295_CR76","doi-asserted-by":"publisher","unstructured":"Zhou T et al (2022) miR-204\u2013containing exosomes ameliorate GVHD-associated dry eye disease. Sci Adv 8(2):eabj9617. https:\/\/doi.org\/10.1126\/sciadv.abj9617","DOI":"10.1126\/sciadv.abj9617"},{"key":"11295_CR77","doi-asserted-by":"publisher","first-page":"84","DOI":"10.21037\/sci.2017.09.06","volume":"4","author":"B Giebel","year":"2017","unstructured":"Giebel B, Kordelas L, B\u00f6rger V (2017) Clinical potential of mesenchymal stem\/stromal cell-derived extracellular vesicles. Stem Cell Invest 4:84\u201384","journal-title":"Stem Cell Invest"},{"issue":"24","key":"11295_CR78","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1089\/scd.2016.0107","volume":"25","author":"L Wang","year":"2016","unstructured":"Wang L et al (2016) Extracellular vesicles released from human umbilical Cord-Derived mesenchymal stromal cells prevent Life-Threatening acute Graft-Versus-Host disease in a mouse model of allogeneic hematopoietic stem cell transplantation. Stem Cells Dev 25(24):1874\u20131883","journal-title":"Stem Cells Dev"},{"issue":"3","key":"11295_CR79","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/stem.2759","volume":"36","author":"S Fujii","year":"2018","unstructured":"Fujii S et al (2018) Graft-Versus-Host disease amelioration by human bone marrow mesenchymal Stromal\/Stem cell-Derived extracellular vesicles is associated with peripheral preservation of Naive T cell populations. Stem Cells 36(3):434\u2013445","journal-title":"Stem Cells"},{"key":"11295_CR80","first-page":"367","volume":"9","author":"K-L Li","year":"2021","unstructured":"Li K-L et al (2021) Exosomes released from human bone Marrow\u2013Derived mesenchymal stem cell attenuate acute Graft-Versus-Host disease after allogeneic hematopoietic stem cell transplantation in mice. Front Cell Dev Biology 9:367\u2013367","journal-title":"Front Cell Dev Biology"},{"issue":"1","key":"11295_CR81","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13287-021-02159-2","volume":"12","author":"W Liu","year":"2021","unstructured":"Liu W et al (2021) Mesenchymal stem cell exosome-derived miR-223 alleviates acute graft-versus-host disease via reducing the migration of donor T cells. Stem Cell Res Ther 12(1):153\u2013153","journal-title":"Stem Cell Res Ther"},{"issue":"7","key":"11295_CR82","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.3390\/ijms20071642","volume":"20","author":"L Kordelas","year":"2019","unstructured":"Kordelas L et al (2019) Individual Immune-Modulatory capabilities of MSC-Derived extracellular vesicle (EV) preparations and Recipient-Dependent responsiveness. Int J Mol Sci 20(7):1642\u20131642","journal-title":"Int J Mol Sci"},{"issue":"8","key":"11295_CR83","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jcyt.2023.03.009","volume":"25","author":"M Bremer","year":"2023","unstructured":"Bremer M et al (2023) Qualification of a multidonor mixed lymphocyte reaction assay for the functional characterization of Immunomodulatory extracellular vesicles. Cytotherapy 25(8):847\u2013857","journal-title":"Cytotherapy"},{"issue":"4","key":"11295_CR84","doi-asserted-by":"publisher","first-page":"e12067","DOI":"10.1002\/jev2.12067","volume":"10","author":"M Li","year":"2021","unstructured":"Li M et al (2021) WJMSC-derived small extracellular vesicle enhance T cell suppression through PD-L1. J Extracell Vesicles 10(4):e12067\u2013e12067","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"11295_CR85","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13045-018-0680-7","volume":"11","author":"P Lai","year":"2018","unstructured":"Lai P et al (2018) A potent Immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD. J Hematol Oncol 11(1):135\u2013135","journal-title":"J Hematol Oncol"},{"issue":"4","key":"11295_CR86","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1002\/stem.1934","volume":"33","author":"S Amarnath","year":"2015","unstructured":"Amarnath S et al (2015) Bone Marrow-Derived mesenchymal stromal cells Harness purinergenic signaling to tolerize human Th1 cells in vivo. Stem Cells 33(4):1200\u20131212","journal-title":"Stem Cells"},{"issue":"5","key":"11295_CR87","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.jcyt.2018.02.372","volume":"20","author":"B Zhang","year":"2018","unstructured":"Zhang B et al (2018) Mesenchymal stromal cell exosome\u2013enhanced regulatory T-cell production through an antigen-presenting cell\u2013mediated pathway. Cytotherapy 20(5):687\u2013696","journal-title":"Cytotherapy"},{"key":"11295_CR88","doi-asserted-by":"publisher","unstructured":"Yeganeh A et al (2023) \u200b in vitro treatment of murine splenocyte with mesenchymal stem cell derived extracellular vesicles altered the mRNA levels of master regulators gene of T cell subsets. Mole Biol Reports 50:3309\u20133316.  https:\/\/doi.org\/10.1007\/s11033-023-08247-1","DOI":"10.1007\/s11033-023-08247-1"},{"issue":"1","key":"11295_CR89","doi-asserted-by":"publisher","first-page":"38339","DOI":"10.1038\/srep38339","volume":"6","author":"J Roos","year":"2016","unstructured":"Roos J et al (2016) miR-146a-mediated suppression of the inflammatory response in human adipocytes. Sci Rep 6(1):38339\u201338339","journal-title":"Sci Rep"},{"issue":"1","key":"11295_CR90","doi-asserted-by":"publisher","first-page":"10299","DOI":"10.1038\/s41598-019-44743-w","volume":"9","author":"E Balducci","year":"2019","unstructured":"Balducci E et al (2019) Extracellular vesicles from T cells overexpress miR-146b-5p in HIV-1 infection and repress endothelial activation. Sci Rep 9(1):10299\u201310299","journal-title":"Sci Rep"},{"issue":"9823","key":"11295_CR91","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","volume":"379","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S et al (2012) Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric Haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 379(9823):1301\u20131309","journal-title":"Lancet"},{"issue":"12","key":"11295_CR92","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/bloodadvances.2017008375","volume":"2","author":"PG Richardson","year":"2018","unstructured":"Richardson PG et al (2018) The use of defibrotide in blood and marrow transplantation. Blood Adv 2(12):1495\u20131509","journal-title":"Blood Adv"},{"key":"11295_CR93","doi-asserted-by":"publisher","first-page":"106541","DOI":"10.1016\/j.intimp.2020.106541","volume":"84","author":"L Guo","year":"2020","unstructured":"Guo L et al (2020) Extracellular vesicles derived from mesenchymal stem cells prevent skin fibrosis in the cGVHD mouse model by suppressing the activation of macrophages and B cells immune response. Int Immunopharmacol 84:106541\u2013106541","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"11295_CR94","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s13287-023-03543-w","volume":"14","author":"H Yang","year":"2023","unstructured":"Yang H et al (2023) Mesenchymal stem cell-based therapy for autoimmune-related fibrotic skin diseases\u2014systemic sclerosis and sclerodermatous graft-versus-host disease. Stem Cell Res Ther 14(1):372","journal-title":"Stem Cell Res Ther"},{"key":"11295_CR95","doi-asserted-by":"crossref","unstructured":"Reis M et al (2018) Mesenchymal stromal cell-Derived extracellular vesicles attenuate dendritic cell maturation and function. Frontiers in Immunology, p 9","DOI":"10.3389\/fimmu.2018.02538"},{"key":"11295_CR96","doi-asserted-by":"publisher","unstructured":"Harrell CR, Djonov V (2022) Volarevic Therapeutic potential of mesenchymal stem cells in the treatment of ocular Graft-Versus-Host disease. Int J Mol Sci 23. https:\/\/doi.org\/10.3390\/ijms232113254","DOI":"10.3390\/ijms232113254"},{"issue":"1","key":"11295_CR97","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13045-022-01315-2","volume":"15","author":"Y Su","year":"2022","unstructured":"Su Y et al (2022) hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype. J Hematol Oncol 15(1):99","journal-title":"J Hematol Oncol"},{"issue":"8","key":"11295_CR98","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jcyt.2023.03.008","volume":"25","author":"RJ Madel","year":"2023","unstructured":"Madel RJ et al (2023) Independent human mesenchymal stromal cell\u2013derived extracellular vesicle preparations differentially attenuate symptoms in an advanced murine graft-versus-host disease model. Cytotherapy 25(8):821\u2013836","journal-title":"Cytotherapy"},{"key":"11295_CR99","doi-asserted-by":"publisher","unstructured":"Hackel A et al (2023) Immunological priming of mesenchymal stromal\/stem cells and their extracellular vesicles augments their therapeutic benefits in experimental graft-versus-host disease via engagement of PD-1 ligands. Front Immunol 14:1078551. https:\/\/doi.org\/10.3389\/fimmu.2023.1078551","DOI":"10.3389\/fimmu.2023.1078551"},{"issue":"2","key":"11295_CR100","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jcyt.2022.09.006","volume":"25","author":"FN Bauer","year":"2023","unstructured":"Bauer FN et al (2023) CD73 activity of mesenchymal stromal cell-derived extracellular vesicle preparations is detergent-resistant and does not correlate with Immunomodulatory capabilities. Cytotherapy 25(2):138\u2013147","journal-title":"Cytotherapy"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11295-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11295-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11295-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:02:47Z","timestamp":1764597767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11295-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11295"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11295-4","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"149"}}